Oculis Holding AG (OCS)
NASDAQ: OCS · Real-Time Price · USD
13.14
0.00 (0.00%)
Aug 18, 2026, 9:58 AM EDT - Market open
Oculis Holding AG Revenue
Oculis Holding AG had revenue of 310.00K CHF in the quarter ending June 30, 2026, with 18.77% growth. This brings the company's revenue in the last twelve months to 1.17M, up 53.33% year-over-year. In the year 2025, Oculis Holding AG had annual revenue of 1.20M with 74.78% growth.
Revenue (ttm)
1.17M CHF
Revenue Growth
+53.33%
P/S Ratio
558.75
Revenue / Employee
19,550 CHF
Employees
60
Market Cap
811.16M USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.20M | 513.00K | 74.78% |
| Dec 31, 2024 | 686.00K | -197.00K | -22.31% |
| Dec 31, 2023 | 883.00K | -29.00K | -3.18% |
| Dec 31, 2022 | 912.00K | -48.00K | -5.00% |
| Dec 31, 2021 | 960.00K | -33.00K | -3.32% |
| Dec 31, 2020 | 993.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Pharming Group | 366.48M |
| Rigel Pharmaceuticals | 276.79M |
| Aclaris Therapeutics | 8.22M |
| DBV Technologies | 5.04M |
| Silence Therapeutics | 615.00K |
OCS News
- 3 days ago - Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - GlobeNewsWire
- 8 days ago - Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis' Position as an Emerging Leading Neuro-Ophthalmology Company - GlobeNewsWire
- 11 days ago - Oculis Reports Q2 2026 Financial Results and Provides Company Update - GlobeNewsWire
- 11 days ago - Oculis Holding AG Earnings release: Q2 2026 - Filings
- 15 days ago - Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses - GlobeNewsWire
- 6 weeks ago - Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference - GlobeNewsWire
- 2 months ago - Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026 - GlobeNewsWire
- 2 months ago - Oculis Holding AG Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts